ACB vs CRON: How Aurora Cannabis and Cronos Group Compare (2026)

Same yardstick, side by side (as of July 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ACB and CRON share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ACB and CRON exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Aurora Cannabis is a Canadian licensed cannabis producer that has spent the past several years reinventing itself. Once one of the most hyped names of the 2018-2019 cannabis boom, it has since exited low-margin Canadian consumer (recreational) cannabis and non-core operations to concentrate on global medical cannabis, which carries higher and more durable margins. In its fiscal 2026 the company reported record medical results: global medical net revenue grew sharply, international medical revenue rose even faster (led by Germany and Poland), and adjusted EBITDA and free cash flow turned meaningfully positive, a real shift from years of cash burn. International medical, its highest-margin segment, now makes up a majority of medical revenue. To feed that demand, Aurora acquired Safari Flower Company, an EU-GMP certified European cultivator, and in February 2026 it completed the divestiture of its controlling stake in Bevo Agtech, its plant-propagation business, further sharpening the focus on medical cannabis.

Full ACB guide

Cronos Group Inc. is a Canada-based, globally focused cannabis company that concentrates on building consumer brands and monetizing intellectual property rather than owning the full, capital-intensive cultivation chain. Its portfolio spans Spinach (a top-selling recreational brand in Canada across edibles, vapes, and flower), PEACE NATURALS (a global medical brand distributed in Canada, Israel, Germany, and the UK), the luxury CBD line Lord Jones, and LIT. Much of the long-running investment story traces to 2019, when tobacco giant Altria invested roughly CA$2.4 billion for a large equity stake, which today sits near 41% ownership. That deal left Cronos with an unusually strong, debt-free balance sheet holding on the order of $800 million in cash and equivalents, a figure large relative to the company's own market value.

Full CRON guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ACB drivers: International medical cannabis growth; Path to sustained profitability.
• CRON drivers: Fortress balance sheet and Altria backing; Brand-led, asset-light model.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central risk is Aurora's capital-structure history: repeated equity raises and a cumulative reverse-split history (roughly 1-for-120 over time) have destroyed per-share value, and further dilution would do so again. For CRON, the biggest risk is regulatory: cannabis remains federally illegal in the US, and reform timelines (rescheduling, SAFE banking, legalization) have slipped repeatedly, so much of the bull case depends on events Cronos cannot control.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ACB if you believe its drivers more; CRON if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ACB and CRON guides.

ACB. These points are qualitative and tied to the asOf date; verify live numbers before acting. For a stock like Aurora, headline revenue growth matters less than whether profitability is durable and whether the company can fund itself without issuing more shares, because dilution has repeatedly overwhelmed operating progress in the past. Be cautious with per-share comparisons across time given the reverse-split history, and always check the current share count, cash position, and latest guidance directly in the filings.

CRON. These figures are approximate, tied to the asOf date, and drawn from 2025 into 2026 reporting; verify live numbers before acting. For a cash-heavy, small-revenue cannabis name, standard earnings multiples are of limited use because so much of the value sits in cash and in an option on policy change rather than in current profits. Compare the market cap to net cash and watch capital allocation as closely as revenue.

Headline figures (approximate, Jul 2026): ACB shows business model Canadian cannabis producer pivoting to higher-margin global medical cannabis, with EU-GMP supply into Germany, Poland, and other international markets, revenue trend Medical (especially international) growing fast, but total revenue expected to ease toward earlier levels as low-margin Canadian consumer and non-core units are exited; verify latest figures, profitability Record fiscal 2026 medical results; adjusted EBITDA and free cash flow turned positive, a shift from years of losses, though management guides fiscal 2027 EBITDA lower, share count Around 59 million common shares as of early 2026, reflecting a heavy cumulative reverse-split history (roughly 1-for-120 over time); CRON shows revenue scale Small but growing; net revenue was a record ~$36 million in Q3 2025, driven by Canadian edibles and international medical sales, balance sheet Debt-free with a large cash position (roughly $800 million in cash and equivalents as reported through 2025), sizable relative to market value, altria ownership Altria holds an approximately 41% equity stake, dating to its ~CA$2.4 billion 2019 investment, profitability Historically loss-making at the operating level; results are volatile and heavily influenced by non-cash items and investment gains or losses.

ACB and CRON are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ACB and CRON exposure against your real portfolio. It is not an investment adviser.